TimTec assembled small targeted compound collection of over 500 compounds-analogs based on three validated O-GlcNAc Transferase inhibitors (following the results of the discovery at Department of Microbiology and Molecular Genetics, HUMS)
Gross, B.J, Kraybill, B.C., Walker, S. Discovery of O-GlcNAc Transferase Inhibitors. Department of Microbiology and Molecular Genetics, Harvard Medical School. JACS Communications, published on Web 09/29/05; J. Am. Chem. Soc. 2005, 127, 14588-14589.
Compounds with proven activity are available from stock:
ST078925 analog-substitute to validated inhibitor #6, Figure 3. of the paper
3-(2-adamantanylethyl)-2-[(4-chlorophenyl)azamethylene]-4-oxo-1,3-thiazaperhyd roine-6-carboxylic acid
OGT inhibitor, ST045849, TT04, treatment reduces beta-cell development:
Filhoulaud, G., et al. The hexosamine biosynthesis pathway is essential for pancreatic beta cell development. J Biol Chem. 2009 Sep 4;284(36):24583-94.